Bank Julius Baer & Co. Ltd Zurich Sells 41,351 Shares of Pfizer Inc. $PFE

Bank Julius Baer & Co. Ltd Zurich reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 5.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 742,418 shares of the biopharmaceutical company’s stock after selling 41,351 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Pfizer were worth $17,996,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the first quarter valued at approximately $27,000. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter valued at $28,000. Harbor Asset Planning Inc. bought a new position in shares of Pfizer in the 2nd quarter worth $29,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer during the first quarter worth $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE opened at $24.41 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.69. The firm’s 50 day moving average price is $24.82 and its two-hundred day moving average price is $24.47. The firm has a market cap of $138.79 billion, a P/E ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analyst Ratings Changes

Several research firms have weighed in on PFE. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Friday, October 31st. Scotiabank initiated coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.